Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

R&D Tax Credit Set For Administrative Expansion, Despite Lapse In Congress

This article was originally published in The Gray Sheet

Executive Summary

A proposal from the Internal Revenue Service set to be finalized this year would expand the research and experimentation tax credit by making prototypes that are sold eligible for the credit. Meanwhile, the tax credit actually expired on Dec. 31, but lawmakers are working to reauthorize it retroactively.

You may also be interested in...



Bid To Make R&D Tax Credit Permanent Fails In Senate Committee; Finance OKs 2-Year Extension

Senators eager to make a popular, two-year-long R&D tax credit permanent were thwarted again July 21 when the Finance Panel approved a package of temporary tax-extenders.

R&D Credit Retroactively Renewed For 2014, But It Stops There

The Senate approved a tax-extenders bill that will retroactively renew the research and development tax credit for 2014 on a 76-16 vote, but the credit expires on Dec. 31. The bill was also approved by the House Dec. 3, and now goes to President Obama, who is expected to sign it.

House Panel Approves Permanent Research Tax Credit, Higher Deductions For Capital Expenses

The House Ways and Means Committee voted to make a recurring research tax credit for businesses permanent, while passing a separate bill to allow increased deductions for certain investments in property, equipment and computer software – both efforts beneficial to device firms.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT033563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel